Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

Overall, both machine learning techniques had an equivalent performance. In general, in those models for detecting Parkinson's disease, DaT-SPECT performed better than biofluid biomarkers. In models for detecting Parkinson's disease patients with mild cognitive impairment, combining DaT-SPECT with phosphorylated-tau-181 resulted in higher accuracy, outperforming DaT-SPECT alone. Classification for Parkinson's disease and mild cognitive impairment may be improved by combining neuroimaging with biofluid biomarkers through machine learning models.

Key findings

Why it matters

This work used machine learning to detect Parkinson's disease and mild cognitive impairment, finding that combining DaT-SPECT with phosphorylated-tau-181 improved accuracy over DaT-SPECT alone. It concerns classification and diagnosis rather than treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 39 of 100.39 of 100 points earned61 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (PLoS ONE)
Journal's citation record 4 / 4 PLoS ONE: journal h-index 594 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Antonio P. Strafella: h-index 73 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Toronto: institution h-index 1,923 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41259329)
Free to read 2 / 2 Free to read
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Dennis, A.-G. P., Martin, S. L., Chen, R. E., Gerretsen, P., & Strafella, A. P. (2025). Using machine learning for detection of Parkinson’s disease and mild cognitive impairment. PLoS ONE. https://doi.org/10.1371/journal.pone.0335541

Vancouver

Dennis A.-GP, Martin SL, Chen RE, Gerretsen P, Strafella AP. Using machine learning for detection of Parkinson’s disease and mild cognitive impairment. PLoS ONE. 2025. doi:10.1371/journal.pone.0335541. PMID: 41259329.

BibTeX

@article{dennis2025-41259329,
  author  = {Dennis, Anthaea-Grace Patricia and Martin, Sarah L. and Chen, Robert E. and Gerretsen, Philip and Strafella, Antonio P.},
  title   = {{Using machine learning for detection of Parkinson’s disease and mild cognitive impairment}},
  journal = {PLoS ONE},
  year    = {2025},
  doi     = {10.1371/journal.pone.0335541},
  pmid    = {41259329},
  url     = {https://doi.org/10.1371/journal.pone.0335541}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →